Michelle E. Bradley

发表

The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists.

D. O'connor, S. Watson, S. Charlton, 2014, Bioorganic & medicinal chemistry letters.

Investigating the molecular mechanisms through which FTY720‐P causes persistent S1P1 receptor internalization

M. Dowling, S. Charlton, A. Sattikar, 2014, British journal of pharmacology.

Investigating the molecular mechanisms through which FTY 720P causes persistent S 1 P 1 receptor internalisation 1

M. Dowling, S. Charlton, A. Sattikar, 2014 .

Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy

S. Watson, S. Charlton, D. Sykes, 2016, Molecular Pharmacology.

Fevipiprant ( QAW 039 ) , a Slowly Dissociating CRTh 2 Antagonist with the Potential for Improved Clinical Efficacy s

S. Watson, S. Charlton, D. Sykes, 2016 .

Potent and Efficacious Inhibition of CXCR2 Signaling by Biparatopic Nanobodies Combining Two Distinct Modes of Action

S. Charlton, T. Laeremans, B. Dombrecht, 2015, Molecular Pharmacology.

SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor

Z. Brown, J. Manini, M. Bradley, 2009, British journal of pharmacology.

Functional desensitization of the β2 adrenoceptor is not dependent on agonist efficacy

S. Charlton, M. Bradley, E. Rosethorne, 2015, Pharmacology research & perspectives.

Design and synthesis of a library of chemokine antagonists.

T. Keller, S. Charlton, David Beer, 2011, Bioorganic & medicinal chemistry letters.

Long Receptor Residence Time of C26 Contributes to Super Agonist Activity at the Human β2 Adrenoceptor

S. Charlton, A. Sattikar, D. Sykes, 2016, Molecular Pharmacology.

Title : Long Receptor Residence Time of C 26 Contributes to Super Agonist Activity at the Human β 2 Adrenoceptor

S. Charlton, A. Sattikar, D. Sykes, 2016 .